Capital expenditure decreased 33.3%
Capital expenditure changed -33.3% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Capital expenditure changed -33.3% from the comparable as-filed period.
Free-cash-flow proxy changed +55.0% from the comparable as-filed period.
Gross profit changed +31.2% from the comparable as-filed period.
Net income changed +65.8% from the comparable as-filed period.
Operating cash flow changed +53.7% from the comparable as-filed period.
Operating income changed +67.7% from the comparable as-filed period.
Revenue changed +33.7% from the comparable as-filed period.
Operating margin moved +2.76 percentage points from the comparable as-filed period.
Research & development changed +12.9% from the comparable as-filed period.
Stock-based compensation changed +13.3% from the comparable as-filed period.
Cash & equivalents changed +7.4% from the comparable as-filed period.
Gross margin moved -0.91 percentage points from the comparable as-filed period.
Capex / revenue moved -0.11 percentage points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.